Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19

Nicola Scichilone, Bruna Lo Sasso, Giulia Bivona, Luisa Agnello, Mario Barbagallo, Rosaria Vincenza Giglio, Concetta Scazzone, Caterina Maria Gambino, Marcello Ciaccio, Marcello Ciaccio, Bruna Lo Sasso, Roberto Muratore, Salvatore Milano, Roberto Muratore, Salvatore Milano

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Objective: The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19.Methods: We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated.Results: Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3-2.95 vs median, 0.82 nmol/L; interquartile range, 0.57-1.03; P <.0001). Receiver operating characteristic curve analysis showed good accuracy of MR-proADM for predicting mortality. A MR-proADM value of 1.73 nmol/L was established as the best cutoff value, with 90% sensitivity and 95% specificity (P <.0001).Conclusion: We found that MR-proADM could represent a prognostic biomarker of COVID-19.
Original languageEnglish
Pages (from-to)493-498
Number of pages6
JournalLaboratory Medicine
Publication statusPublished - 2021

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19'. Together they form a unique fingerprint.

Cite this